S. Gorelov

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

Christopher G. Wood, Pramod K. Srivastava, Ronald M. Bukowski et al. · The Lancet · 2008 · 328 citations

Urology, Surgical Oncology, Versus Observation +10

A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC)-a preliminary report

C. G. Wood, Bernard Escudier, S. Gorelov et al. · Journal of Clinical Oncology · 2004 · 15 citations

Surgical Oncology, Renal Pathology, Immunology +19

Survival update from a multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence

C. G. Wood, Priyanka Srivastava, Louis Lacombe et al. · Journal of Clinical Oncology · 2009 · 15 citations

Surgical Oncology, Vitespen Versus Observation, Immunology +20

A MULTICENTRE, RANDOMISED, PHASE 3 TRIAL OF A NOVEL, AUTOLOGOUS, THERAPEUTIC VACCINE (VITESPEN) VS. OBSERVATION AS ADJUVANT THERAPY IN PATIENTS AT HIGH RISK OF RECURRENCE AFTER NEPHRECTOMY FOR RENAL CELL CARCINOMA

Peter F.A. Mulders, Christopher G. Wood, S. Gorelov et al. · European Urology Supplements · 2008 · 10 citations

Vaccination, Urology, Oncology +11